All In Biotech

Drug Trial Radar · NCT03230838

MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)

A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Versus Meropenem in Pediatric Subjects With Complicated Urinary Tract Infection, Including Pyelonephritis

Last checked: Nov 20, 2026Latest source record: May 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 134 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

134

Actual

Start

Apr 26, 2018

Primary completion

Dec 3, 2020

Study completion Dec 3, 2020

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jul 26, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 7 days, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety and tolerability of MK-7625A (ceftolozane/tazobactam) compared with that of meropenem in pediatric participants with cUTI, including pyelonephritis.

Conditions

  • Complicated Urinary Tract Infection
  • Pyelonephritis

Interventions

  • Ceftolozane/TazobactamDrug

    12 to \<18 years of age: Ceftolozane 1 g/dose; Tazobactam 0.5 g/dose via a 60-minute (±10 minutes) IV infusion every 8 hours for 7-14 days. \<12 years of age: Ceftolozane 20 mg/kg with Tazobactam 10 mg/kg (not to exceed Ceftolozane 1 g and Tazobactam 0.5 g) via a 60-minute (±10 minutes) IV infusion every 8 hours for 7-14 days.

  • MeropenemDrug

    Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 7 to 14 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With ≥1 Adverse Events (AEs)Time frame: Up to Day 88
  2. Number of Participants Discontinuing Study Therapy Due to AETime frame: Up to Day 15

Locations

52 sites in 10 countries. Site status is shown where the registry gives one.

  • Children's Hospital - Los Angeles ( Site 2509)

    Los Angeles, California

  • Children's Hospital of Orange County ( Site 2502)

    Orange, California

  • Rady Children's Hospital-San Diego ( Site 2505)

    San Diego, California

  • Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 2519)

    Chicago, Illinois

  • Our Lady of the Lake Hospital ( Site 2512)

    Baton Rouge, Louisiana

  • St. Louis Children's Hospital ( Site 2508)

    St Louis, Missouri

  • SUNY Upstate Medical University Hospital ( Site 2510)

    Syracuse, New York

  • Wake Forest Baptist Health ( Site 2520)

    Winston-Salem, North Carolina

  • Baylor College Of Medicine ( Site 2515)

    Houston, Texas

  • Pan and Aglaia Kyriakou Children s Hospital ( Site 0780)

    Athens, Attica, Greece

  • University of Athens - Aghia Sophia Childrens Hospital ( Site 0730)

    Athens, Attica, Greece

  • Athens University Hospital ATTIKON ( Site 0790)

    Athens, Attica, Greece

  • Hippokration General Hospital of Thessaloniki ( Site 0700)

    Thessaloniki, Thessaloníki, Greece

  • General University Hospital of Larissa ( Site 0740)

    Larissa, Thessaly, Greece

  • Semmelweis Egyetem ( Site 0810)

    Budapest, Hungary

  • Heim Pal Orszagos Gyermekgyogyaszati Intezet ( Site 0801)

    Budapest, Hungary

  • Debreceni Egyetem Klinikai Kozpont ( Site 0803)

    Debrecen, Hungary

  • PTE AOK Klinikai Kozpont ( Site 0809)

    Pécs, Baranya, Hungary

  • SZTE Szent-Gyorgyi Albert Klinikai Kozpont ( Site 0804)

    Szeged, Csongrád megye, Hungary

  • SzSzBMK es Egyetemi Oktatokorhaz Josa Andras Oktatokorhaz ( Site 0808)

    Nyíregyháza, Szabolcs-Szatmár-Bereg, Hungary

  • Instituto Nacional de Pediatria ( Site 1201)

    Mexico City, Mexico

  • Hospital Infantil de Mexico Federico Gomez ( Site 1203)

    Mexico City, Mexico

  • Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 1202)

    Guadalajara, Jalisco, Mexico

  • Instituto Tecnologico y de Estudios Superiores de Monterrey ( Site 1204)

    Monterrey, Nuevo León, Mexico

  • Wojewodzki Szpital Obserwacyjno Zakazny ( Site 1606)

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

  • Szpital Uniwersytecki nr 1 im. Dr. Antoniego Jurasza w Bydgoszczy ( Site 1600)

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

  • Wojewodzki Szpital Zespolony im. Rydgiera ( Site 1607)

    Torun, Kuyavian-Pomeranian Voivodeship, Poland

  • Uniw. Szpital Dzieciecy w Krakowie ( Site 1609)

    Krakow, Lesser Poland Voivodeship, Poland

  • Instytut Centrum Zdrowia Matki Polki ( Site 1602)

    Lodz, Łódź Voivodeship, Poland

  • SPZOZ im. Dzieci Warszawy w Dziekanowie Lesnym ( Site 1608)

    Łomianki, Masovian Voivodeship, Poland

  • Spitalul Clinic de Urgenta pentru Copii Brasov ( Site 1703)

    Brasov, Romania

  • Institutul National de Boli Infectioase Prof. Dr. Matei Bals ( Site 1706)

    Bucharest, Romania

  • Spitalul Clinic de Urgenta pentru Copii Maria Sklodowska Curie ( Site 1707)

    Bucharest, Bucharest, Romania

  • Spit. Cl. de Urg. Copii Cluj Napoca ( Site 1708)

    Cluj-Napoca, Cluj, Romania

  • Russian Pediatric Clinical Hospital ( Site 1808)

    Moscow, Moscow, Russia

  • St.Petersburg State Pediatric Medical University ( Site 1811)

    Saint Petersburg, Sankt-Peterburg, Russia

  • Smolensk Regional Clinical Hospital ( Site 1800)

    Smolensk, Smolensk Oblast, Russia

  • Regional Childrens Clinical Hospital ( Site 1805)

    Stavropol, Stavropol Kray, Russia

  • Molotlegi Street ( Site 1903)

    Pretoria, Gauteng, South Africa

  • Inkosi Albert Luthuli Central Hospital ( Site 1902)

    Durban, KwaZulu-Natal, South Africa

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.